Barclays Raises PT on Hims & Hers Health (HIMS) Stock

Additionally, it besides demonstrates the removal of ineligible overhang for Hims & Hers Health, Inc. (NYSE:HIMS)’s stock. As per the firm, the broader marketplace has been underappreciating the company’s accidental from caller products.

Notably, successful a antithetic release, Hims & Hers Health, Inc. (NYSE:HIMS) announced a collaboration with Novo Nordisk arsenic portion of a caller strategy for value nonaccomplishment attraction treatments involving GLP-1s. In the US, the institution aims to connection GLP-1 customers entree to a wide assortment of medications that are FDA-approved, and supply compounded semaglutide via the level connected a constricted scale.

Hims & Hers Health, Inc. (NYSE:HIMS) is simply a consumer-first wellness and wellness platform, connecting consumers to licensed healthcare professionals.

While we admit the imaginable of HIMS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.